Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Erlotinib in Advanced Biliary Tumors
NCT00356889Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2006
- Primary completion
- Oct 2008
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, erlotinib in cholangiocarcinoma (CCA), gallbladder carcinoma, sponsored by National Cancer Institute. Started May 2006; status: completed.
02
Drugs
bevacizumaberlotinib
03
Conditions
cholangiocarcinoma (CCA)gallbladder carcinoma
Beyond the preview
Go deeper on NCT00356889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00356889.